Molecular diagnostics and liquid biopsy approaches in diffuse midline glioma: an update and literature review
Year: 2026
Type: review
Abstract: PURPOSE: Diffuse midline gliomas (DMGs), H3 K27-altered, are aggressive childhood central nervous system tumors that remain almost uniformly fatal. Historically diagnosed radiographically as diffuse intrinsic pontine glioma (DIPG), these tumors are now defined by integrated anatomic and molecular criteria encompassing H3 K27-mutant, EZHIP-overexpressing, and EGFR-altered subtypes. Advances in tissue sampling have transformed understanding of their molecular landscape, but their eloquent location, the sampling bias inherent to stereotactic biopsy, and the impracticality of repeated tissue sampling have motivated interest in biofluid-based approaches. Liquid biopsy is being investigated as a complementary modality for molecular characterization, longitudinal monitoring, and detection of progression and resistance. METHODS: A narrative review of the literature was performed using PubMed/MEDLINE for articles published through 31 July 2026, supplemented by a ClinicalTrials.gov search performed on the same date. Eligible articles described liquid biopsy methodologies, biomarker substrates, or clinical applications in DMG or DIPG; a separate, explicitly labeled category of enabling or methodologically relevant studies performed on tissue or in other tumor types was retained. RESULTS: We summarize the WHO CNS5 molecular definition of DMG, the role and limitations of tissue-based diagnosis, the spectrum of liquid biopsy substrates and platforms with study-level performance data, and the incorporation of cerebrospinal fluid (CSF) sampling into interventional DMG trials. We distinguish exploratory biomarker collection from analytically or clinically validated testing, and we address CSF access, safety, selection bias, and turnaround time. CONCLUSIONS: Liquid biopsy in DMG remains investigational. No application, whether molecular diagnosis, response monitoring, pseudoprogression adjudication, or treatment adaptation, is currently prospectively validated for clinical decision-making. Standardized, prospective, multi-institutional studies with predefined thresholds are required.
Source: Child s Nervous System
Authors: Sudarshawn Damodharan, Daphne Li
Institution: Advocate Lutheran General Hospital
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,790
OpenAlex ID: W7236758975
